Global prediabetes market is anticipated to grow at a CAGR of 7.2% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing product expansion and new drugs in the market. For instance, in January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analog in the UK. This drug can be prescribed to people with prediabetes and...

  Global prediabetes market is anticipated to grow at a CAGR of 7.2% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing product expansion and new drugs in the market. For instance, in January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analog in the UK. This drug can be prescribed to people with...